Spectrum Pharmaceuticals develops and commercializes cancer therapies, including Rolvedon (formerly eflapegrastim), a long-acting G-CSF for treating chemotherapy-induced neutropenia (CIN). The FDA's ...
Spectrum Brands Holdings faces structural concerns despite operational strengths, with sluggish revenue growth and declining sales in key divisions raising red flags for investors. Tariff impacts and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback